Merck & Co., Inc. (MRK)
Merck Stock Slides on Lowered Adjusted EPS Guidance
Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast.
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Options Traders Blast 2 Pharma Socks After Earnings
Pharmaceutical giants Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results.
Merck (MRK) Q2 Earnings and Revenues Top Estimates
Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago.
Merck beats profit and sales expectations amid Keytruda strength, but provides mixed full-year outlook
Shares of Merck & Co. MRK, +2.01% slipped 0.6% in premarket trading Tuesday, after the drug maker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer treatment Keytruda, while providing a mixed full-year outlook. The company swung to net income of $5.46 billion, or $2.14 a share, from a loss of $5.98 billion, or $2.35 a share, in the same period a year ago.
Merck second quarter tops Street view on strong Keytruda sales
Merck & Co posted higher-than-expected second-quarter results on Tuesday on strong growth of its blockbuster cancer immunotherapy Keytruda, the world's best-selling prescription medicine.
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vaccines portfolios and a new cardiovascular drug. The pharmaceutical giant also raised its full-year sales forecast to a range of $63.4 billion to $64.4 billion, however it lowered its adjusted profit guidance to between $7.94 and $8.04 per share.
Germany's Merck raises 2024 sales forecast
Germany's Merck on Friday further its forecast for the group and said it now expects net sales to be between 20.7 billion euros ($22.49 billion) and 22.1 billion euros for 2024.
Is An Earnings Beat In The Cards For Merck Stock?
Merck (NYSE: MRK) will report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $15.9 billion and adjusted earnings of $2.20, slightly ahead of the street estimates.
Countdown to Merck (MRK) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE
Merck & Co will announce Q2 2024 earnings on July 30th. Merck's share price has risen 65% in the past 3 years, driven by the success of Keytruda, the world's best-selling drug. Keytruda revenues were up 25% year-on-year in Q1 2024, contributing nearly 45% of Merck's total revenues last quarter.
